Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet, University of Copenhagen, DK-2100 Copenhagen, Denmark.
Department of Oncology, Herlev Hospital, University of Copenhagen, DK-2730 Herlev, Denmark.
Viruses. 2022 Dec 22;15(1):34. doi: 10.3390/v15010034.
Second primary cancer (SPC) is the second most common cause of death among patients diagnosed with head and neck cancer. This study examined the risk of SPC following oropharyngeal squamous cell carcinoma (OPSCC) and the impact of human papillomavirus (HPV) on survival following SPC. The study was a population-based, retrospective study including all patients diagnosed with OPSCC in eastern Denmark from 2000-2020 who received curative intended treatment. The incidence rate ratio (IRR), age-adjusted incidence rates (AAIR), and hazard ratios (HR) were calculated. A total of 2584 patients with primary OPSCC were included (median follow-up time: 3.1 years), with 317 patients (12.3%) diagnosed with SPC. The risk of SPC was approximately five times the occurrence of cancer in the general population (IRR: 4.96). The median time to SPC after a primary OPSCC was 2.0 years (interquartile range (IQR) = 0.6-4.2 years). HPV-positive (HPV+) patients had a significantly longer median time to SPC, and a significant better survival compared to HPV-negative (HPV-) patients. SPC was most frequently found in lungs, head, and neck (LHN) for HPV- OPSCC patients and lungs followed by gender-specific (prostate, ovaries, or endometrium) for HPV+ OPSCC. There was a significant difference between the two groups when distributed between "within" or "outside" LHN. Patients with SPC outside LHN had a significant better overall survival. This knowledge should be considered during post-treatment surveillance and might guide targeted imaging.
第二原发癌(SPC)是头颈部癌症患者死亡的第二大主要原因。本研究调查了口咽鳞状细胞癌(OPSCC)患者发生 SPC 的风险以及 SPC 后人类乳头状瘤病毒(HPV)对生存的影响。该研究为基于人群的回顾性研究,纳入了 2000 年至 2020 年期间在丹麦东部接受根治性治疗的所有 OPSCC 患者。计算了发病率比(IRR)、年龄调整发病率(AAIR)和风险比(HR)。共纳入 2584 例原发性 OPSCC 患者(中位随访时间:3.1 年),其中 317 例(12.3%)患者诊断为 SPC。SPC 的风险约为普通人群癌症发生风险的五倍(IRR:4.96)。原发性 OPSCC 后发生 SPC 的中位时间为 2.0 年(四分位距(IQR)= 0.6-4.2 年)。HPV 阳性(HPV+)患者发生 SPC 的中位时间明显更长,与 HPV 阴性(HPV-)患者相比生存情况显著更好。HPV- OPSCC 患者的 SPC 最常发生于肺部、头颈部(LHN),HPV+ OPSCC 患者的 SPC 最常发生于肺部,其次为性别特异性部位(前列腺、卵巢或子宫内膜)。两组之间在“LHN 内”或“LHN 外”分布时存在显著差异。LHN 外发生 SPC 的患者总生存情况显著更好。这些知识应在治疗后监测期间加以考虑,并可能指导针对性的影像学检查。
Cancer Epidemiol Biomarkers Prev. 2019-7-29
JAMA Otolaryngol Head Neck Surg. 2019-12-1
J Otolaryngol Head Neck Surg. 2013-5-29
Pathogens. 2023-12-14
Cancers (Basel). 2023-9-14
Viruses. 2023-5-6
Otolaryngol Head Neck Surg. 2021-4
J Biomed Inform. 2019-5-9